Stock Markets July 31, 2026 03:32 PM

Integer Shares Spike as KKR Reportedly Nears Go-Private Deal

Buyout chatter and a strategic review propel the medical-device contract manufacturer to a fresh 52-week high

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
ITGR KKR

Integer Holdings Corp stock jumped sharply after reports surfaced that private equity firm KKR is close to agreeing to acquire the medical device contract developer and manufacturer at about $127 per share. The move comes after a Board-led strategic review initiated in Integer's first-quarter 2026 earnings call and follows activist investor engagement and heightened private equity interest in the company's unique public exposure as a medical device CDMO.

Integer Shares Spike as KKR Reportedly Nears Go-Private Deal
ITGR KKR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Reports say KKR is close to acquiring Integer for roughly $127 per share, driving a 20.3% intraday share surge and a 52-week high of $123.50.
  • Integer's Board launched a strategic review during its Q1 2026 earnings call—an effort described as focused on maximizing shareholder value and influenced by activist investor engagement.
  • Analysts note that comparable medical device CDMO transactions have traded in the mid-teens EV/EBITDA, and some sell-side firms had already revised ratings and targets ahead of potential deal news.

Integer Holdings Corp shares climbed 20.3% in afternoon trading to $121.32, touching an intraday 52-week high of $123.50, after reports indicated that KKR is nearing a deal to take the company private at roughly $127 per share. Media accounts suggested a formal announcement could arrive as soon as next week.

The potential acquisition would be the end point of a strategic review that Integer's Board of Directors formally launched during the company’s first-quarter 2026 earnings call. The Board characterized that process as aimed at maximizing shareholder value. The review followed engagement by an activist investor and growing interest from private equity buyers attracted to Integer’s status as the only publicly traded contract development and manufacturing organization (CDMO) in the medical device space.

Integer’s position as a standalone, publicly listed medical-device CDMO is notable because that asset class has tended to command premium valuations in private markets. Analysts cited by the market have pointed toward comparable CDMO transactions completing in the mid-teens on an enterprise value-to-EBITDA basis, a level that implied material upside relative to where Integer had been trading prior to today’s move.

Research houses had already adjusted recommendations in light of Integer’s strategic review. Oppenheimer upgraded the stock to Outperform and set a $115 price target after the Board announced the review. KeyBanc kept an Overweight rating with a $104 target.

U.S. equity markets provided a supportive backdrop for risk assets on the day, with the S&P 500 up 0.75%, the Dow Jones Industrial Average rising 0.64%, and the Nasdaq Composite advancing 0.98%. Even so, Integer’s intraday spike far outpaced the broader market move, driven primarily by the buyout reports.

Market participants cited three elements that converged to produce the dramatic single-day gain: a concrete go-private bid at a meaningful premium to prevailing prices, a strategic review that had signaled the possibility of a transaction to investors, and a generally constructive macro environment for equities. Together, those factors pushed Integer to levels not seen in over a year and into the valuation range analysts had flagged as reasonable in a sale scenario.


Disclosure: The article reports on market developments and analyst coverage as described above.

Risks

  • Deal completion is not certain - the reported acquisition is framed conditionally ("if completed"), so shareholders face execution and regulatory risk; this affects the healthcare and private-equity sectors.
  • Timing remains uncertain - while a formal announcement was described as possible as soon as next week, that timing was not guaranteed, leaving near-term volatility for Integer shares and related M&A-sensitive equities.
  • Valuation assumptions tied to private-market CDMO multiples may not materialize for all bidders or in every transaction, posing a risk to expectations about transaction pricing and its impact on comparable healthcare and industrials assets.

More from Stock Markets

S&P Moves System1 Up After Debt Swap, Cuts Interest Burden and Leverage Outlook Jul 31, 2026 Bovespa Edges Higher as Financials, Industrials and Materials Lead Gains Jul 31, 2026 Toronto market closes lower as telecoms, materials and IT drag S&P/TSX down 0.79% Jul 31, 2026 U.S. Stocks Finish Higher as Consumer Services, Energy and Telecoms Lead Gains Jul 31, 2026 Jersey Mike’s prices IPO at $23, lists on NYSE as JMKE Jul 31, 2026